Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., Ltd., plans to transfer 38.5 million H-shares of Boan Biotechnology to Luye Geneora Holding Limited by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1]. Group 1 - Boan Biotechnology's stock price increased by 3.31% to HKD 9.04, with a trading volume of HKD 365 million [1]. - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating it into its system to access its antibody drug pipeline, technology platform, and production assets [1]. - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1].

Group 1 - The stock of Luye Pharma Group (博安生物) increased by nearly 5%, reaching HKD 9.12 with a trading volume of HKD 358 million as of the report time [1] - On January 21, Luye Pharma announced that its board was informed by its controlling shareholder, Luye Pharma Group, about a plan to transfer 38.5 million H-shares to the market through its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., on January 22, 2026 [1] - Luye Pharma previously acquired 98% of the shares of Luye Geneora Holding Limited, integrating its antibody drug pipeline, technology platform, and production assets, with Shandong Luye Pharmaceutical Co., Ltd. becoming the core holding entity [1] Group 2 - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Luye Pharma's shares [1] - Luye Pharma serves as a key vehicle for Luye Pharma Group's transition from traditional small molecules to biopharmaceuticals, aiding in the establishment of a dual research and development system for "chemical drugs + biological drugs" [1]

Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., plans to transfer 38.5 million H-shares of Boan Biotechnology by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1] Group 1: Company Developments - Boan Biotechnology's stock rose nearly 5%, trading at HKD 9.12 with a transaction volume of HKD 358 million [1] - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating its antibody drug pipeline, technology platform, and production assets [1] - By 2025, Shandong Luye Pharmaceutical will hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1] Group 2: Strategic Importance - Boan Biotechnology plays a crucial role in Luye Pharma's dual-line R&D system, combining chemical and biopharmaceutical development [1]

数据来源：wind 进一步展望生物科技领域的投资前景。大家已经了解，港股为生物科技公司上市提供了得天独厚的条 件，那么当前为何要投资港股的生物科技公司？这可以从宏观背景层面进行分析。当前美联储正处于降 息周期，大家也清楚，在降息环境下，包括美国在内的境外资金更倾向于流出美股市场，转而寻找具有 成长价值的投资机会，而非停留在美股市场追求低息无风险收益，而港股很可能成为其优先选择。 在美联储新一轮防御式降息周期中，港股资产展现出比以往更优的收益弹性和流动性前景。这对于以港 股生物科技为代表的成长板块的估值修复和业绩增长，具有重要的指引意义。下方列出的时间序列图 表，重点标记了恒生生物科技指数与美联储降息周期时间节点的重要关联。可以看到，2019年7月至 2020年美联储降息期间，恒生生物科技指数就展现出了较好的业绩弹性。而从2024年至2025年年底，乃 至如今迈入2026年，在降息周期的大背景下，恒生生物科技指数很可能展现出更优的收益弹性表现。这 是我们从宏观政策角度分析得出的结论。 回归国内政策层面，未来境内尤其是港股上市的生物科技公司将获得哪些政策支持？我们能看到，行业 政策正全链条支持创新药发展。其中一个 ...

Key Points - Tianfu Communication expects a net profit increase of 40%-60% year-on-year by 2025, driven by revenue growth in both active and passive product lines [1] - Nanmin Group signed a 296 million yuan equipment sales contract, accounting for 38.08% of the company's audited revenue for 2024 [1] - Hongbaoli's epoxy propylene comprehensive technology transformation project has entered the preliminary preparation stage for trial production [1] - Tengjing Technology signed a sales order worth 89.15 million yuan for high-end optical devices in the optical communication field, catering to customized needs of downstream OCS switch manufacturers [1] - Hanjian Heshan is planning to acquire 52.51% of Liaoning Xingfu New Materials Co., Ltd., leading to a stock suspension [1] - Zhongtian Precision Decoration's subsidiary HBM2e has begun mass production, while HBM3/3e is advancing to tape-out [1] Investment & Contracts - Hualan Co. plans to invest 450 million yuan in its wholly-owned subsidiary Lingqing Smart, which focuses on AI innovative drug research and development solutions and services [1] - Binhai Energy intends to invest 548 million yuan in the construction of porous carbon and silicon-carbon anode material projects [1] Financing & Capital Increase - Luvi Optoelectronics plans to raise no more than 1.38 billion yuan through a private placement [1] - Tianhua New Energy is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Xinlitai intends to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] Performance - Shanghai Yizhong expects a net profit increase of 760.18%-903.54% year-on-year by 2025 [1] - Jin'an Guoji anticipates a net profit increase of 656%-871%, with a year-on-year increase in the production and sales volume of copper-clad laminates [1] - Hekang New Energy expects a net profit increase of 386%-628% by 2025 [1] - Limin Co. forecasts a net profit increase of 471.55%-514.57% year-on-year by 2025 [1] - Baiao Intelligent expects a net profit increase of 228%-338% by 2025 [1] - Dajin Heavy Industry anticipates a net profit increase of 122%-153% by 2025, with rapid growth in project delivery amounts and numbers in the overseas offshore wind power market [1] - Demingli expects a net profit increase of 85%-128% by 2025, with Q4 performance exceeding expectations [1] - Penghui Energy expects a net profit of 17 million to 23 million yuan in 2025, marking a turnaround from losses [1]

普祺医药向香港联交所主板递交上市申请书，中信证券和民银资本担任联席保荐人。 普祺医药是一家专注于免疫炎症领域的生物科技公司，普美昔替尼凝胶为全球首款用于治疗特应性皮炎 的JAK抑制剂凝胶，已完成成人及12至17岁青少年特应性皮炎适应症的III期临床试验，并正拓展至2至 11岁儿童特应性皮炎。普美昔替尼鼻喷雾剂为全球首款用于治疗季节性过敏性鼻炎的临床阶段JAK抑制 剂鼻喷雾剂，正处于针对成年人季节性过敏性鼻炎的III期临床试验阶段，并正拓展至青少年季节性过敏 性鼻炎及成年人常年性过敏性鼻炎。 PG-033片剂具有同类首创潜力的TRPV3抑制剂，针对瘙痒症，处于I期临床研究阶段，并拓展至奥姆斯 特德综合征相关的顽固性瘙痒与角化过度症。PG-018片剂具有同类首创潜力的JAK1-ROCK双靶点抑制 剂，用于治疗自身免疫性肾病，处于I期临床研究阶段。PG-040滴眼液具有同类首创潜力的ROCK-JAK 双靶点滴眼液，作为青光眼的新治疗方案。 自身免疫性疾病和过敏性疾病药物市场在全球及中国均呈现快速增长态势，特应性皮炎药物市场在中国 预计将从2024年的110亿元人民币增长至2033年的502亿元人民币。 ...

智通财经APP获悉，据港交所1月21日披露，北京普祺医药科技股份有限公司(简称：普祺医药)向港交所主板递交上市申请书，中信证券、民银资本为联席保 荐人。 公司简介 招股书显示，普祺医药是一家专注于免疫炎症领域的生物科技(Biotech)公司，致力于成为局部递送靶向疗法的领导者。公司自2016年成立以来，以创新原创 设计及精准局部递送为核心能力，深耕慢性炎症性疾病治疗领域，旨在提供兼具疗效、安全性及长期患者满意度的创新解决方案。 基于对免疫炎症相关信号通路的深入了解，公司发现：多种慢性疾病的核心病理进程，与细胞外免疫信号传递及转录调控(以Janus激酶-信号转导及转录激活 因子("JAK-STAT")通路为代表)及免疫细胞活化调控通路的协同作用高度相关，并基于此洞察形成了具备同类首创潜力的创新产品管线，凭借原创设计分 子，针对多个存在重大未满足医疗需求的适应症进行布局。 凭借对这些信号通路的深入理解以及综合创新药物研发体系，普祺医药开发了后期核心产品PG-011(普美昔替尼)，其有两种剂型，包括针对特应性皮炎的普 美昔替尼凝胶与针对过敏性鼻炎的普美昔替尼鼻喷雾剂。公司亦拥有多元化候选产品组合，包括针对瘙痒症的P ...

Group 1 - The core viewpoint of the news is that Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a leader in targeted therapy for immune inflammation [1] - The company was established in 2016 and focuses on innovative original design and precise local delivery in the treatment of chronic inflammatory diseases [1] - Puxi Pharmaceutical aims to provide innovative solutions that balance efficacy, safety, and long-term patient satisfaction [1] Group 2 - Puxi Pharmaceutical has developed its core product PG-011 (Pumeixinine), which comes in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis [3] - The company also has a diversified pipeline of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma [3]

Group 1 - The core viewpoint of the article is that Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, aiming to become a leader in targeted therapy for immune inflammation [1] - The company was established in 2016 and focuses on innovative design and precise local delivery in the treatment of chronic inflammatory diseases, providing effective, safe, and long-term patient satisfaction solutions [1] Group 2 - Puxi Pharmaceutical has developed its core product PG-011 (Pumeixinine), which comes in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis [3] - The company also has a diversified pipeline of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma [3]

Clene Inc. Conference Call Summary Company Overview - Clene Inc. is a clinical stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis) [1] Key Accomplishments and FDA Interactions - Clene has achieved an in-person meeting with the FDA this quarter, marking the fifth meeting in 14 months to discuss extensive biomarker and survival data [2] - The company presented significant biomarker analyses showing reductions in neurofilament and GFAP (glial fibrillary acidic protein), which are associated with longer survival in ALS patients [3][4] - Clene aims to file a new drug application (NDA) under the accelerated approval pathway, utilizing biomarker data as a surrogate endpoint due to missed primary endpoints in previous studies [5][6] Biomarker Data and Clinical Evidence - The company has demonstrated that reductions in neurofilament levels are quantitatively associated with improved survival, with a noted reduction of 9%-10% linked to lower mortality risk [8] - Clene is pursuing a three-pronged approach to validate the biomarker benefits, including proving substantial biomarker benefit, establishing an independent association with mortality, and demonstrating consistent clinical benefits [7][9] Future Plans and Timeline - The FDA meeting is scheduled for later this quarter, with the intent to file the NDA in the second quarter of 2024 if the FDA concurs with the data presented [11][12] - If accepted, commercialization could begin by early 2025, with aspirations to approve CNM-Au8 for ALS patients [13] Financing and Cash Runway - Clene raised approximately $6 million at a price of $6.50 per share through a tranche financing, extending its cash runway by an additional quarter [17] - Future tranches are planned, with potential raises of $7 million at $7 per share and $15 million at a $12.50 strike price upon approval [18] Industry Context and Need for New Treatments - There are over 30,000 ALS patients in the U.S., with a uniform mortality rate of 2-4 years without treatment, highlighting the urgent need for new drugs [19] - Clene is also working to reauthorize funding for ALS research at the Congressional level, emphasizing the critical need for advancements in treatment options [19] Conclusion - Clene Inc. is positioned to make significant strides in ALS treatment through its ongoing FDA interactions and biomarker research, with a clear plan for future drug application and funding strategies [20]